<PAGE>
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 23, 2000
REGISTRATION NO. 333-
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------------
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
--------------------------
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
<TABLE>
<S> <C> <C>
DELAWARE 6770 06-139-7316
(STATE OR OTHER (PRIMARY STANDARD (I.R.S. EMPLOYER
JURISDICTION INDUSTRIAL IDENTIFICATION NO.)
OF INCORPORATION OR CLASSIFICATION CODE
ORGANIZATION) NUMBER)
</TABLE>
251 BALLARDVALE STREET
WILMINGTON, MASSACHUSETTS 01887
(978) 658-6000
(Address, including zip code, and telephone number,
including area code, of Registrant's principal executive offices)
THOMAS F. ACKERMAN, CHIEF FINANCIAL OFFICER
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
251 BALLARDVALE STREET
WILMINGTON, MASSACHUSETTS 01887
(978) 658-6000, EXT. 1225
(978) 694-9504 (FAX)
(NAME, ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE
NUMBER, INCLUDING AREA CODE, OF AGENT FOR SERVICE)
--------------------------
COPIES TO:
<TABLE>
<S> <C>
MARY E. WEBER, ESQ. RICHARD D. TRUESDELL, JR., ESQ.
Ropes & Gray Davis Polk & Wardwell
One International Place 450 Lexington Avenue
Boston, Massachusetts 02110 New York, New York 10017
(617) 951-7000 (212) 450-4000
(617) 951-7050 (fax) (212) 450-4800 (fax)
</TABLE>
--------------------------
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: As soon as
practicable after this Registration Statement becomes effective.
If any of the securities being registered on this Form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, check the following box. / /
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective
registration statement for the same offering. /X/ 333-35524
If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. / /
If this Form is a post-effective amendment filed pursuant to Rule 462(d)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. / /
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. / /
--------------------------
CALCULATION OF REGISTRATION FEE
<TABLE>
<CAPTION>
PROPOSED MAXIMUM PROPOSED MAXIMUM
TITLE OF EACH CLASS OF SECURITIES AMOUNT TO BE OFFERING PRICE AGGREGATE AMOUNT OF
TO BE REGISTERED REGISTERED PER UNIT(1) OFFERING PRICE(1) REGISTRATION FEE
<S> <C> <C> <C> <C>
Common Stock, par value $.01 per
share........................... 1,725,000 $16.00 $27,600,000 $7,287
</TABLE>
(1) Estimated solely for the purpose of computing the amount of the registration
fee pursuant to Rule 457(a) under the Securities Act of 1933.
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
<PAGE>
INCORPORATION BY REFERENCE OF REGISTRATION STATEMENT ON FORM S-1, FILE NO.
333-35524
Charles River Laboratories International, Inc. (the "Company") hereby
incorporates by reference into this Registration Statement on Form S-1 in its
entirety the Registration Statement on Form S-1 (File No. 333-35524) declared
effective on June 23, 2000 by the Securities and Exchange Commission (the
"Commission"), including each of the documents filed by the Company with the
Commission and incorporated or deemed to be incorporated by reference therein
and all exhibits thereto.
EXHIBITS
The following documents are filed as exhibits to this Registration
Statement.
<TABLE>
<CAPTION>
EXHIBIT
NUMBER DESCRIPTION
------- -----------
<S> <C>
5.1 Opinion of Ropes & Gray
23.1 Consent of PricewaterhouseCoopers LLP
23.2 Consent of Ropes & Gray (included in Exhibit 5.1)
</TABLE>
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant
has duly caused this Registration Statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Boston, State of
Massachusetts, on the 23rd day of June, 2000.
<TABLE>
<S> <C> <C>
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
By: /s/ THOMAS F. ACKERMAN
---------------------------------------------
Thomas F. Ackerman
CHIEF FINANCIAL OFFICER
</TABLE>
Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed by the following persons in the
capacities indicated on June 23, 2000.
<TABLE>
<CAPTION>
SIGNATURE TITLE
--------- -----
<C> <S>
*
------------------------------------------- President, Chief Executive Officer (Principal
James C. Foster Executive Officer) and Chairman
Chief Financial Officer (Principal Financial
/s/ THOMAS F. ACKERMAN Officer) and Senior Vice President, Finance
------------------------------------------- and Administration (Principal Accounting
Thomas F. Ackerman Officer)
*
------------------------------------------- Director
Robert Cawthorn
*
------------------------------------------- Director
Stephen D. Chubb
*
------------------------------------------- Director
Thompson Dean
*
------------------------------------------- Director
Stephen C. McCluski
*
------------------------------------------- Director
Reid S. Perper
*
------------------------------------------- Director
Douglas E. Rogers
</TABLE>
II-1
<PAGE>
<TABLE>
<CAPTION>
SIGNATURE TITLE
--------- -----
<C> <S>
*
------------------------------------------- Director
Samuel Thier
*
------------------------------------------- Director
William Waltrip
*
------------------------------------------- Director
Henry C. Wendt
</TABLE>
<TABLE>
<S> <C> <C> <C>
By: /s/ THOMAS F. ACKERMAN
-------------------------------------- Attorney-in Fact
Thomas F. Ackerman
</TABLE>
II-2
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT
NUMBER DESCRIPTION
------- -----------
<S> <C>
5.1 Opinion of Ropes & Gray
23.1 Consent of PricewaterhouseCoopers LLP
23.2 Consent of Ropes & Gray (included in Exhibit 5.1)
</TABLE>
